Beta-blockade in the management of systolic dysfunction.
The concept that heart failure is simply the consequence of impaired pump function is now outmoded. Congestive heart failure is a neuroendocrine syndrome in with activation of the adrenergic nervous system and specific endocrine pathways is integral to its pathogenesis. It is now clear that chronic increases in adrenergic drive associated with heart failure have detrimental effects on myocardial function. The use of BAAs is now standard therapy for people who develop heart failure caused by systolic dysfunction. Beta-blockade may have a role in the management of dogs with heart failure.
Abbott
Jonathan A
JA
Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Technical Institute, Phase II Duckpond Drive, Blacksburg, VA 24061, USA. abbottj@vt.edu
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D006333:Heart Failure / Q000188:drug therapy / Q000662:veterinary*; D006801:Humans; D013599:Systole
D000319:Adrenergic beta-Antagonists